Blockchain Registration Transaction Record

Lantern Pharma Secures Key Patent for AI-Guided Cancer Therapy LP-184

Lantern Pharma receives US patent for LP-184 therapy using a three-gene biomarker signature identified by its AI platform. Ovarian, liver, kidney, and thyroid cancer patients may benefit.

This news matters because it marks a step toward more personalized cancer treatment, potentially improving outcomes for patients with ovarian, liver, kidney, and thyroid cancers by using a biomarker signature to identify those most likely to benefit from LP-184. The patent also validates Lantern's AI platform, which could accelerate development of targeted therapies and reduce trial failures, offering hope for more effective and less toxic treatments.